Non-small cell lung cancer with synchronous oligometastatic disease at the time of initial diagnosis. Impact of multimodal treatment on prognosis

Lung, Respiratory and Thoracic Cancer

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment

Lung Cancer

Bartolomeo V, Jongbloed M, Huijs JWJ, Filippi AR, van den Borne BEEM, Pitz C, Gietema H, Degens J, Youssef-El Soud M, Steens M, Dursun S, van Geffen WH, de Boer P, De Ruysscher DKM, Hendriks LEL

doi: 10.1016/j.lungcan.2026.109337

Lung, Respiratory and Thoracic CancerCOVID-19

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Eur J Cancer

Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A

doi: 10.1016/j.ejca.2026.116902

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

IMDYLLTRA^® in Relapsed Small Cell Lung Cancer: Translating a New T-cell Engager Approach into Clinical Practice

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Lung, Respiratory and Thoracic Cancer

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

Lung Cancer

Roden RT, Harmsen WS, Breen WG, Moffett JN, Pulsipher SD, Olivier KR, Garces YI, Park SS, Merrell KW, Sarkaria JN, Owen D

doi: 10.1016/j.lungcan.2025.108789

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Lung Cancer

Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K

doi: 10.1016/j.lungcan.2025.108772

Lung, Respiratory and Thoracic Cancer

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Target Oncol

Sanborn RE, Zhou C, Tang KJ, Cho BC, Cheng S, Popat S, Ono A, Lu S, Majem M, Aguilar A, Del Rosario Garcia Campelo M, Hayashi H, Lee KY, Lee SH, Delmonte A, Alatorre-Alexander J, Richardson G, Santos V, Dooms C, Sabari JK, Shu CA, Girard N, Mansfield AS, Park K, Xia Y, Bhattacharya A, Buyukkaramikli N, Perualila N, Diels J, Acharya S, Chandler C, Proskorovsky I, Dearden L, Wortman-Vayn H, Mahadevia PJ, Knoblauch RE, Agrawal T, Baig M, Felip E

doi: 10.1007/s11523-025-01182-0

Lung, Respiratory and Thoracic Cancer

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Lung Cancer

Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC, European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group

doi: 10.1016/j.lungcan.2025.108798

Related content

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer

IMDYLLTRA® in Relapsed Small Cell Lung Cancer: Translating a New T-cell Engager Approach into Clinical Practice

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

IMDYLLTRA^® in Relapsed Small Cell Lung Cancer: Translating a New T-cell Engager Approach into Clinical Practice